Cover Image

PAPERBACK
$43.50



View/Hide Left Panel

TABLE 9.6 Sensitivity Analysis: Effect of Discount Rate on Annualized Present Value of Expenditures to Achieve the Benefits of Various Vaccine Candidates

 

Discount Rate

 

Central Analysis, 0.05

0.02

0.10

Vaccine

Rank

Expenditure ($ million)

Rank

Expenditure ($ million)

Rank

Expenditure ($ million)

Rabies (live vector virus)

1

16

1

21

1

10

V. cholera (attenuated live)

2

24

2

29

2

18

V. cholera (inactivated)

3

44

3

51

3

34

E. coli (attenuated live)

4

69

4

96

4

42

Shigella

5

92

6

128

5

55

Yellow fever

6

93

5

107

6

75

Rabies (glycoprotein)

7

139

7

182

8

112

Rabies (Vero cell derived)

8

147

8

193

9

119

S. typhi (aa-strain)

9

152

9

195

7

103

Dengue

10

242

10

341

11

140

M. leprae

11

271

12

417

10

137

S. typhi (Ty21a)

12

358

11

390

12

312

H. influenzae b

13

527

13

663

14

364

Streptococcus group A

14

554

14

749

13

344

Japanese encephalitis

15

614

17

806

15

398

Rotavirus (LPBVR)

16

655

15

802

18

475

Rotavirus (RMRV)

17

656

16

802

19

476

N. meningitidis

18

708

18

945

17

447

E. coli (purified antigens)

19

722

20

1,021

16

415

Rotavirus (HPBRV)

20

853

19

957

23

709

Malaria (multivalent)

21

857

21

1,177

20

516

Malaria (monovalent)

22

967

23

1,236

21

653

RSV (attenuated live)

23

983

22

1,203

24

711

Hepatitis A (attenuated live)

24

1,058

24

1,373

22

697

Streptococcus pneumoniae

25

1,310

25

1,604

25

948

Parainfluenza

26

1,697

26

2,267

26

1,068

RSV (glycoprotein)

27

1,964

27

2,405

27

1,420

Hepatitis A (polypeptide)

28

4,029

28

5,383

28

2,542

Hepatitis B

29

8,859

29

9,664

29

7,700



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement